[Market Focus] Kolon TissueGene Surges 8.58% on Hopes for TG-C Clinical Trials

Shares of Kolon TissueGene are showing strong performance due to expectations for the expansion of the osteoarthritis treatment market.

As of 2:11 p.m. on November 21, Kolon TissueGene was trading at 63,300 won, up 5,000 won (8.58%) from the previous trading day. At one point during the session, the stock rose as much as 12.69% to 65,700 won.

On this day, Seo Geunhee, a researcher at Samsung Securities, stated, "Two Phase 3 clinical trials for TG-C (osteoarthritis treatment) in the United States are scheduled to be completed next year," and added, "This product has already completed Phase 3 clinical trials and obtained product approval in Korea. It is not about new verification, but rather confirming the reproducibility of existing data."

Seo also explained, "If the patient population in the ongoing Phase 3 clinical trials in the United States is homogeneous, the structural risk of clinical failure is low." He continued, "Financially, the company issued convertible bonds (CB) worth 122.5 billion won last September, allocating the funds for clinical trial costs, production, and preparations for commercialization. If both pain relief and cartilage regeneration are achieved, the commercial value of the product can be re-evaluated."

This content was produced with the assistance of AI translation services.